Topics:
Gastrointestinal Cancers • Medical Oncology
How do you decide on first line treatment for a patient with metastatic colon cancer with dMMR, a HER2 mutation and no mutations in KRAS or BRAF?
Answer from: Medical Oncologist at Academic Institution
Immune checkpoint inhibitors (pembrolizumab: KEYNOTE177, NEJM Dec-2020 OR nivolumab/ipilimumab: CheckMate-142, JCO 2018) are approved as first line treatment options for MMR-deficient tumors. KEYNOTE-177 study supported the efficacy (PFS) of pembrolizumab vs. chemotherapy in first line setting in pa...
Sign in or Register to read more